)
Barbara Domayne-Hayman
Entrepreneur-in-Residence,
Francis Crick Institute
Barbara has worked on the commercial side of life sciences for over thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara is Entrepreneur-in-residence at the Francis Crick Institute, where amongst other things, she co-founded and is now Chair of the KQ Labs accelerator for data-driven health startups from across the UK. Barbara is a member of the investment committees of LifeArc Ventures, and Cambridge Enterprise Ventures. Previously, Barbara was Chair of Puridify until its acquisition by GE (Cytiva). She was CEO of Stabilitech and prior to that was Commercial Director at Arrow Therapeutics until its acquisition by AstraZeneca.